Table 1.
Comprehensive evaluation of the scope, depth, and quality of pharmacogenomic evidence for cardiovascular drugs.
| Cardiovascular drugs, N=71 | |||||
|---|---|---|---|---|---|
| Positive PGxa | 51 (71.8%) | ||||
| Clinical summary warranted | 23 (32.4%) | ||||
|
| |||||
| Drug/variant pairs, N=884 | |||||
|
| |||||
| Classification
|
Clinical summaries warranted
|
||||
| N | N | Level 1 | Level 2 | Level 3 | |
| 3+ Studies & PharmGKB | 33 | 25 (75.8%) | 4 | 6 | 15 |
| PharmGKB only | 43 | 10 (23.3%) | 0 | 5 | 5 |
| 3+ Studies only | 37 | 9 (24.3%) | 0 | 4 | 5 |
| Other (None of above) | 771 | 48 (6.2%) | 0 | 32 | 16 |
|
|
|
||||
| 884 | 92 (10.4%) | 4 | 47 | 41 | |
71 cardiovascular drugs with pharmacogenomic information were identified and critically reviewed, encompassing analysis of 884 unique drug/variant pairs; of the 71 drugs, 51 had positive pharmacogenomic findings in the literature (“Positive PGx”). The existence of 3 or more positive supporting publications for any given drug/variant pair (“3+ Studies”) and/or existence of a PharmGKB clinical annotation (“PharmGKB”) were the criteria used to stratify drug/variant pairs into one of four groups.